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I NFECTIOUS complications and sepsis are associated 
with high morbidity and mortality in human and exper-
imental small bowel transplantation. l Enteric microflora is 
thought to play an important role in the genesis of these 
infections. The transit of viable bacteria through the intes-
tinal epithelium into the lamina propria, and consequently 
to the mesenteric lymph nodes, peritoneal cavity, and other 
previously sterile tissues, is called bacterial translocation 
(BT). Translocation of microorganisms from the GI tract 
has been demonstrated in animal and human studies.v 
Although BT has been suggested to be the mechanism 
responsible for the high rate of infections occurring after 
clinical small bowel transplantation (SBTx), data are not 
available. Bacterial overgrowth, alteration of the mucosal 
barrier function, consequence of preservation injury or 
acute rejection (AR), and the use of potent immunosup-
pression have all been considered responsible for BT in 
SBTx.4 - 6 The aim of this study was to evaluate the corre-
lation of BT with these events. 
MATERIALS AND METHODS 
Fifty pediatric SBTx recipients (26 boys and 24 girls) with a 
follow-up ranging from 20 days to 6 years (mean :!: SO: 30 :!: 10 
months) under tacrolimus and prednisone immunosuppression 
were analyzed. Among these, 14 received isolated small bowel 
(SB), 28 liver and SB (LSB), and 8 multivisceral (MV) allografts. A 
colon graft was included in 16 patients (4 in SB, 8 in SBL, 4 in MV). 
Blood, stool, liver biopsies, and peritoneal fluid were collected 
when infection was clinically suspected or as part of follow-up, and 
cultures were performed using standard microbiological tech-
niques. Approximately 4000 cultures were evaluated in the study. 
BT episodes were considered when microorganisms were found 
simultaneously in blood or liver biopsy and feces, whereas positive 
central line blood samples without peripheral confirmation were 
discarded. Acute rejection (AR) episodes were considered only if 
confirmed histologically and counted as one if within a 3-week 
duration. The Fisher Exact test was used for statistical analysis. 
RESULTS AND DISCUSSION 
BT (average of 2.0 episodes/patient) was evident in 44% of 
patients (36% in SB, 50.0% in SBL, 37.5% in MV group) 
most frequently caused by enterococci. staphylococci, en-
terobacter, and klebsiella. The presence of the colon graft 
was associated with a higher bacterial count in the stool 
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(100% cultures >1 x 106 CFU) and BT (75% of patients) 
compared to the patients without colon (84.6% cultures 
>1 x 106 CFU; BT 33.3% of patients). Furthermore, the 
type of transplant profoundly affected the rate of BT (group 
with vs without colon: SB = 40% vs 25%; LSB = 100% vs 
30%; MV = 25% vs 50%). AR took place in 36% of all BT 
episodes. From a total of 167 episodes of AR only 9.6% 
were followed by BT, while an additional 5.2% were 
followed by bacteriemia or positive tissue culture without 
fecal confirmation of the bacteria at examination. However, 
the rate of BT was observed in a significantly higher number 
of patients with cold ischemia time (CIT) >9 hours when 
compared to patients with CIT <9 hours (76% vs 20.8%, 
P = .002). 
CONCLUSIONS 
This study shows that: (1) even though. during AR, mucosal 
damage occurs and immunosuppression is substantially 
increased, this is not accompanied by an increased BT rate; 
(2) the presence of colon graft caused an increment in-
crease in fecal bacterial counts and BT: (3) the duration of 
CIT strongly influences the rate of BT after SBTx in 
children. Taken together these data provide a new view of 
the mechanisms associated with infections after SBTx. 
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